Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
Armon Azizi(Stanford University), Tian Yi Zhang(Stanford University), David Iberri(Stanford University), Shyam A. Patel(UMass Memorial Health Care), Peter L. Greenberg(VA Palo Alto Health Care System), Jason Gotlib(Stanford University), Ritika Dutta(Stanford University), Ravindra Majeti(Stanford University), William Shomali(Stanford Medicine), Asiri Ediriwickrema(Stanford University), Gabriel N. Mannis(Memorial Sloan Kettering Cancer Center), Bruno C. Medeiros(Stanford Medicine)
Cited by 29
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k